References
- [1] Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114: 1537-1544
- [2] Ansell SM. Nivolumab in the treatment of Hodgkin lymphoma. Clin Canc Res 2016; 23 (7): 1-5
- [3] Baughman RP. Technical aspects of bronchoalveolar lavage: recommendations for a standard procedure. Semin.Respir Crit Care Med 2007; 28: 475-485
- [4] Brandhorst G, Petrova DT, Weigand S, Eberle C, von AN, Schmitz J, Schultze FC, Raddatz D, Karaus M, Oellerich M, Walson PD. Lack of correlation between Treg quantification assays in inflammatory bowel disease patients. World J Gastroenterol. 2015; 21: 3325-3329
- [5] Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquee L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schroder A, Shepherd FA. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014; 15: 59-68
- [6] Chcialowski A, Chorostkowska-Wynimko J, Fal A, Pawlowicz R, Domagala-Kulawik J. Recommendation of the Polish Respiratory Society for bronchoalveolar lavage (BAL) sampling, processing and analysis methods. Pneumonol.Alergol.Pol. 2011; 79: 75-98
- [7] Chmielowicz B, Obojski A, Barczyk A, Sozanska E, Kycler Z, Demkow U, Domagala-Kulawik J. [Methodology of induced sputum induction and processing--recommendation of Polish Respiratory Society]. Pneumonol.Alergol.Pol. 2008; 76: 378-394
- [8] Dabrowska M, Grubek-Jaworska H, Domagala-Kulaw ik J, Bartoszewicz Z, Kondracka A, Krenke R, Nejman P, Chazan R. [Diagnostic usefulness of selected tumor markers (CA125, CEA, CYFRA 21-1) in bronchoalveolar lavage fluid in patients with non-small cell lung cancer]. Pol.Arch.Med.Wewn. 2004; 111: 659-665
- [9] Domagala-Kulawik J. BAL in the diagnosis of smoking-related interstitial lung diseases: review of literature and analysis of our experience. Diagn.Cytopathol. 2008; 36: 909-915
- [10] Domagala-Kulawik J. Effects of cigarette smoke on the lung and systemic immunity. J.Physiol Pharmacol. 2008; 59 Suppl 6: 19-34
- [11] Domagala-Kulawik J. The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention. Transl.Lung Cancer Res. 2015; 4: 177-190
- [12] Domagala-Kulawik J, Droszcz P, Kraszewska I, Chazan R. Expression of Fas antigen in the cells from bronchoalveolar lavage fluid (BALF). Folia Histochem.Cytobiol. 2000; 38: 185-188
- [13] Domagala-Kulawik J, Hoser G, Dabrowska M, Safianowska A, Chazan R. CD4+/CD25+ cel l s in systemic inflammation in COPD. Scand.J.Immunol. 2011; 73: 59-65
- [14] Domagala-Kulawik J, Hoser G, Doboszynska A, Kawiak J, Droszcz W. [Phenotype of lymphocytes in bronchoalveolar lavage fluid of patients with lung fibrosis in the course of scleroderma]. Pneumonol. Alergol.Pol. 1995; 63: 382-388
- [15] Domagala-Kulawik J, Hoser G, Safianowska A, Grubek-Jaworska H, Chazan R. El evat ed TGF- -beta1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer. Arch. Immunol Ther.Exp.(Warsz.) 2006; 54: 143-147
- [16] Domagala-Kulawik J, Maskey-Warzecowska M. T-regulatory cells in COPD or tumour environment. Eur.Respir.J. 2009; 34: 284-286
- [17] Domagala-Kulawik J, Osinska I. [Immune alterations in lung cancer - the new therapeutic approach]. Pneumonol.Alergol.Pol. 2014; 82: 286-299
- [18] Domagala-Kulawik J, Osinska I, Hoser G. Mechanisms of immune response regulation in lung cancer. Transl.Lung Cancer Res. 2014; 3: 15-22
- [19] Dummer CD, Carpio VN, Goncalves LF, Manfro RC, Veronese FV. FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance. Transpl.Immunol. 2012; 26: 1-10
- [20] Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013; 73: 3591-3603
- [21] Fan F, Samuel S, Evans KW, Lu J, Xia L, Zhou Y, Sceusi E, Tozzi F, Ye XC, Mani SA, Ellis LM. Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Med. 2012; 1: 5-16
- [22] Fridman WH, Remark R, Goc J, Giraldo NA, Becht E, Hammond SA, Damotte D, Dieu-Nosjean MC, Sautes-Fridman C. The immune microenvironment: a major player in human cancers. Int.Arch. Allergy Immunol. 2014; 164: 13-26
- [23] Frydecka I, Kosmaczewska A, Bocko D, Ciszak L, Wolowiec D, Kuliczkowski K, Kochanowska I. Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia. Br.J Cancer 2004; 90: 2042-2048
- [24] Galon J, Pages F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA. The immune score as a new possible approach for the classification of cancer. J Transl.Med. 2012; 10: 1
- [25] Giavina-Bianchi M, Giavina-Bianchi P, Sotto MN, Muzikansky A, Kalil J, Festa-Neto C, Duncan LM. Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma. J Immunol.Res. 2015; 2015: 761378
- [26] Giraldo NA, Becht E, Vano Y, Sautes-Fridman C, Fridman WH. The immune response in cancer: from immunology to pathology to immunotherapy. Virchows Arch. 2015; 467: 127-135
- [27] Hai J, Sakashita S, Allo G, Ludkovski O, Ng C, Shepherd FA, Tsao MS. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models. J Thorac.Oncol. 2015; 10: 1172-1180
- [28] Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N.Engl.J Med. 2013; 369: 134-144
- [29] Hermanowicz-Salamon J, Domagala-Kulawik J, Maskey-Warzechowska M, Chazan R. [Macrophage phenotype in induced sputum in asthma subjects]. Pneumonol.Alergol.Pol. 2006; 74: 101-105
- [30] Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N.Engl.J Med. 2010; 363: 711-723
- [31] Hoser G, Domagala-Kulawik J, Droszcz P, Droszcz W, Kawiak J. Lymphocyte subsets differences in smokers and nonsmokers with primary lung cancer: a flow cytometry analysis of bronchoalveolar lavage fluid cells. Med.Sci.Monit. 2003; 9: BR310-BR315
- [32] Hoser G, Kawiak J, Domagala-Kulawik J, Kopinski P, Droszcz W. Fl ow cytometric evaluation of lymphocyte subpopulations in BALF of healthy smokers and nonsmokers. Folia Histochem.Cytobiol. 1999; 37: 25-30
- [33] Hou TZ, Qureshi OS, Wang CJ, Baker J, Young SP, Walker LS, Sansom DM. A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells. J Immunol. 2015; 194: 2148-2159
- [34] Hus I, Kawiak J, Tabarkiewicz J, Radej S, Hoser G, Bojarska-Junak A, Schmitt M, Giannopoulos K, Dmoszynska A, Rolinski J. Immunotherapy with irradiated autologous leukemic cells in patients with B-CLL in early stages. Oncol.Rep. 2008; 20: 443-451
- [35] Hus I, Schmitt M, Tabarkiewicz J, Radej S, Wojas K, Bojarska-Junak A, Schmitt A, Giannopoulos K, Dmoszynska A, Rolinski J. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia 2008; 22: 1007-1017
- [36] Kawalec M, Jakobisiak M, Skorski T, Kawiak J. Immunogenicity of cyclophosphamide-treated leukaemia cells. Folia Biol.(Praha) 1982; 28: 334-343
- [37] Kawalec M, Skorski T, Kawiak J. Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells. Invest New Drugs 1988; 6: 169-172
- [38] Kawiak J, Hus I.Rolinski J, Tabarkiewicz J, Wojas K, Kosek A, Bojarska-Junak A, Kowal M, Górska M, Dmoszyńska A Immunotherapy of B-cell Patients with autologous Irradiated Leukemic cells and BCG, Pol J Environmental Studies supl II, 2005; 14: 187-191.
- [39] Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR. Pr ogrammed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? J Thorac.Oncol. 2015; 10: 985-989
- [40] Kruger C, Greten TF, Korangy F. Immune based therapies in cancer. Histol.Histopathol. 2007; 22: 687-696
- [41] Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736
- [42] Lin X, Chen M, Liu Y, Guo Z, He X, Brand D, Zheng SG. Advances in distinguishing natural from induced Foxp3(+) regulatory T cells. Int.J Clin.Exp.Pathol. 2013; 6: 116-123
- [43] Liu H, Zhang T, Ye J, Li H, Huang J, Li X, Wu B, Huang X, Hou J. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol. Immunother. 2012; 61: 1849-1856
- [44] Liu J, Lluis A, Illi S, Layland L, Olek S, von ME, Schaub B. T r egulatory cells in cord blood-FOXP3 demethylation as reliable quantitative marker. PLoS.One. 2010; 5: e13267
- [45] Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, Old LJ, Odunsi K. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc.Natl.Acad.Sci.U.S.A 2010; 107: 7875-7880
- [46] McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA, Hoffmuller U, Baron U, Olek S, Bluestone JA, Brusko TM. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol. 2011; 186: 3918-3926
- [47] Moschella F, Torelli GF, Valentini M, Urbani F, Buccione C, Petrucci MT, Natalino F, Belardelli F, Foa R, Proietti E. Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients’ blood cells: implications for cancer chemoimmunotherapy. Clin. Cancer Res. 2013; 19: 4249-4261
- [48] Neller MA, Lopez JA, Schmidt CW. Antigens for cancer immunotherapy. Semin.Immunol. 2008; 20: 286-295
- [49] Okamura T, Fujio K, Sumitomo S, Yamamoto K. Roles of LAG3 and EGR2 in regulatory T cells. Ann. Rheum.Dis. 2012; 71 Suppl 2: i96-100
- [50] Okamura T, Sumitomo S, Morita K, Iwasaki Y, Inoue M, Nakachi S, Komai T, Shoda H, Miyazaki J, Fujio K, Yamamoto K. TGF-beta3-expressing CD4+CD25(-)LAG3+ regulatory T cells control humoral immune responses. Nat.Commun. 2015; 6: 6329
- [51] Osinska I, Domagala-Kulawik J. [Bronchoalveolar lavage in lung cancer-diagnostic value and assessment of the anti-cancer immune response]. Postepy Hig.Med.Dosw.(Online.) 2013; 67: 1119-1127
- [52] Ott PA, Hodi FS, Buchbinder EI. Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. Front Oncol. 2015; 5: 202
- [53] Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin.Cancer Res. 2013; 19: 5300-5309
- [54] Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013; 39: 38-48
- [55] Pan Q, Li Q, Liu S, Ning N, Zhang X, Xu Y, Chang AE, Wicha MS. Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches. Stem Cells 2015; 33: 2085-2092
- [56] Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, Sanmamed MF, Melero I. Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Curr.Opin.Immunol. 2014; 27: 89-97
- [57] Pizzurro GA, Tapia IJ, Sganga L, Podhajcer OL, Mordoh J, Barrio MM. Cytokine-enhanced maturation and migration to the lymph nodes of a human dying melanoma cell-loaded dendritic cell vaccine. Cancer Immunol.Immunother. 2015; 64(11): 1393-406.
- [58] Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin. Oncol. 2015; 33: 1974-1982
- [59] Putnam AL, Safinia N, Medvec A, Laszkowska M, Wray M, Mintz MA, Trotta E, Szot GL, Liu W, Lares A, Lee K, Laing A, Lechler RI, Riley JL, Bluestone JA, Lombardi G, Tang Q. Cl inical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am.J Transplant. 2013; 13: 3010-3020
- [60] Radojcic V, Bezak KB, Skarica M, Pletneva MA, Yoshimura K, Schulick RD, Luznik L. Cycl ophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol.Immunother. 2010; 59: 137-148
- [61] Rolinski J, Hus I. Br eaking immunotolerance of tumors: a new perspective for dendritic cell therapy. J Immunotoxicol. 2014; 11: 311-318
- [62] Ruben JM, van den Ancker W, Bontkes HJ, Westers TM, Hooijberg E, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA. Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines. Cancer Immunol.Immunother. 2014; 63: 335-345
- [63] Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell-McGuinn K, Hensley ML, Konner J, Tew W, Spriggs DR, Hoffman EW, Venhaus R, Pan L, Salazar AM, Diefenbach CM, Old LJ, Gnjatic S. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin.Cancer Res. 2012; 18: 6497-6508
- [64] Saha A, Chatterjee SK. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Scand.J Immunol. 2010; 71: 70-82
- [65] Salvi S, Fontana V, Boccardo S, Merlo DF, Margallo E, Laurent S, Morabito A, Rijavec E, Dal Bello MG, Mora M, Ratto GB, Grossi F, Truini M, Pistillo MP. Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 2012; 61: 1463-1472
- [66] Schmitt EG, Williams CB. Generation and function of induced regulatory T cells. Front Immunol. 2013; 4: 152
- [67] Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautes-Fridman C, Ma Y, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology. 2012; 1: 1323-1343
- [68] Shih K, Arkenau HT, Infante JR. Cl inical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014; 74: 1993-2013
- [69] Shrimali RK, Janik JE, Abu-Eid R, Mkrtichyan M, Khleif SN. Programmed death-1 & its ligands: promising targets for cancer immunotherapy. Immunotherapy. 2015; 7: 777-792
- [70] Skirecki T, Hoser G, Domagala-Kulawik J, Kawiak J. Characterization of a new small cell lung cancer (SCLC) cell line STP54 derived from a metastatic bioptate of a combined type of SCLC with Non-SCLC component. Folia Histochem.Cytobiol. 2009; 47: 111-115
- [71] Skorski T, Kawalec M, Kawiak J. Mechanisms of immunological response induced in CD2F1 mice by administration of semisyngeneic L 1210 leukemia cells treated with cyclophosphamide. Immunol. Invest 1987; 16: 33-43
- [72] Stadler S, Weina K, Gebhardt C, Utikal J. New therapeutic options for advanced non-resectable malignant melanoma. Adv.Med.Sci. 2015; 60: 83-88
- [73] Sundar R, Soong R, Cho BC, Brahmer JR, Soo RA. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014; 85: 101-109
- [74] Takiguchi Y, Sekine I, Iwasawa S, Kurimoto R, Tatsumi K. Chronic obstructive pulmonary disease as a risk factor for lung cancer. World J Clin.Oncol. 2014; 5: 660-666
- [75] Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, Chen L. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci.Transl.Med. 2012; 4: 127ra37
- [76] van Montfoort N, van der Aa E, Woltman AM. Understanding MHC class I presentation of viral antigens by human dendritic cells as a basis for rational design of therapeutic vaccines. Front Immunol. 2014; 5: 182
- [77] Wang C, Yu X, Wang W. A meta-analysis of efficiacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer. Medicine 2016; 95: 52
- [78] Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Pr ogrammed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014; 94: 107-116
- [79] Wojas J, Pajtasz-Piasecka E. [Dendritic cell-regulatory T-cell interaction]. Postepy Hig.Med.Dosw. (Online.) 2010; 64: 167-174
- [80] Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. Nivolumab plus ipilimumab in advanced melanoma. N.Engl.J Med. 2013; 369: 122-133
- [81] Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit S, Grosso JF, Netto G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG, Vignali DA. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012; 72: 917-927
- [82] Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat.Rev.Drug Discov. 2013; 12: 130-146